Lisdexamfetamine

ID: lisdexamfetamine

Aliases: Vyvanse, Elvanse, LDX, lisdexamfetamine dimesylate

Type: compound

Route/form: oral prescription stimulant capsule or chewable tablet

Status: approved_or_labelled

Evidence level: approved / labelled

Best data tier: approved label + human controlled/review

Support scope: human, review/regulatory

Source types: label, meta_analysis, regulatory_review, systematic_review

Linked sources: 4

Broad outcomes: Brain / mood / sleep, Cardiovascular / lipids / blood pressure, Fat loss / metabolic health, PEDs / AAS / thermogenics, Safety / regulatory

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• dextroamphetamine prodrug
• dopamine/norepinephrine signaling after conversion
• ADHD and binge-eating disorder labelled use

Optimization domains

• ADHD
• binge eating disorder
• wakefulness
• stimulant
• cognition
• appetite
• cardiovascular

Research basis

• Lisdexamfetamine is an oral prodrug converted to dextroamphetamine, with labelled ADHD and adult binge-eating-disorder indications.
• It is relevant to stimulant comparisons because prodrug conversion changes pharmacokinetics and may alter onset, duration, and abuse-liability profile versus immediate-release amphetamine.

Limits, risks, and missing evidence

• It remains a Schedule II amphetamine prodrug with misuse, insomnia, appetite, blood-pressure/heart-rate, and psychiatric warnings.
• Longer duration can be helpful or problematic depending on sleep timing, anxiety, and cardiovascular context.

Risk flags

• controlled substance
• misuse addiction
• stimulant
• blood pressure
• tachycardia
• insomnia
• anxiety panic
• psychosis mania
• cardiac screening
• appetite weight loss

Linked papers, labels, and reviews

1. DailyMed label: VYVANSE (lisdexamfetamine dimesylate)
   label / dailymed_vyvanse_label
   Label for lisdexamfetamine capsules/chewables; ADHD and adult binge-eating-disorder indications plus stimulant misuse, cardiovascular, psychiatric, and appetite warnings.
2. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
   systematic_review / pmc_amphetamines_adult_adhd_cochrane_2018
   Cochrane review including dexamphetamine, lisdexamfetamine, and mixed amphetamine salts in adult ADHD.
3. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in Adult ADHD
   meta_analysis / sage_adult_adhd_stimulants_meta_2019
   Systematic review/meta-analysis comparing adult ADHD stimulant and modafinil trial evidence.
4. FDA approves multiple generics of ADHD and BED treatment
   regulatory_review / fda_vyvanse_generics_stimulant_warning_2023
   FDA context for lisdexamfetamine generics and standardized prescription-stimulant warnings on misuse, cardiovascular reactions, BP/HR, psychiatric adverse reactions, and serotonin syndrome.